JNJ-81201887

Phase 2Small molecule

Johnson & Johnson

JNJ-81201887 is one of 12 small molecule programs targeting Geographic Atrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Geographic AtrophyRecruiting

Geographic AtrophyPhase 2

Recruiting

Competition

Competitive Landscape

18 competitors in Geographic Atrophy

#DrugCompanyPhaseTrials

Lucentis

Roche

Approved

2 2

Eylea

Regeneron

Approved

1 3

Izervay

Astellas

Approved

3 4

Farxiga

AstraZeneca

Phase 2

1 5

Tecfidera

Biogen

Phase 2

1 6

Tinlarebant

BBelite Bio, Inc

Phase 3

1 7

Vonaprument

AAnnexon, Inc.

Phase 3

2 8

Opregen

Roche

Phase 2

1 9

BS01

BBionic Sight LLC

Phase 2

1 10

JNJ-81201887

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

PreclinicalRecruiting

Geographic Atrophy

NCT06635148

Clinical

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT05811351·305 enrolled

Geographic Atrophy1 trial

Long-term Extension Study for Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Preclinical·NCT06635148·274 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for JNJ-81201887. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-81201887 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-81201887. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Johnson & Johnson

JNJ-81201887

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

Geographic Atrophy1 trial

References

Drug Info

Quick Facts

Related News